Sandip Ganguly

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro et al. · Journal of Clinical Oncology · 2023 · 74 citations

Medicine, Oncology, Pharmacology +17

Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India

Joydeep Ghosh, Sandip Ganguly, Debapriya Mondal et al. · JCO Global Oncology · 2020 · 53 citations · Full text

Medicine, Oncology, Chemotherapy +11

HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

Santam Chakraborty, Sanjoy Chatterjee, Selvamani Backianathan et al. · Radiotherapy and Oncology · 2022 · 40 citations

Pharmacy, Radiation Oncology, Dose-response Modeling +13

Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial

Sanjoy Chatterjee, Santam Chakraborty, Santam Chakraborty et al. · Trials · 2020 · 29 citations · Full text

Medicine, Oncology, Clinical Radiation Oncology +7